Table of Contents
Chapter 1 NASH Biomarkers Market: Methodology and Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates and forecast timeline
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity flow analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.2 Volume price analysis (model 2)
1.6.2.1 Approach 2: Volume price analysis
1.6.2.2 Revenue modeling
1.7 List of Secondary Sources
1.8 List of Primary Sources
Chapter 2 NASH Biomarkers Market: Executive Summary
2.1 Market Summary
Chapter 3 NASH Biomarkers Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Rising prevalence of chronic liver diseases
3.3.1.2 Increasing demand for non-invasive diagnostics for NASH biomarkers
3.3.1.3 Rising investment by government and private organizations in R&D for NASH biomarkers therapeutics
3.3.2 Market Restraint Analysis
3.3.2.1 Side-effects and risks associated with NASH therapeutics
3.4 Porter’s Five Forces Analysis
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Regulatory Framework
3.7 Pipeline Analysis
Chapter 4 NASH Biomarkers Market: Competitive Landscape
4.1 Recent developments & impact analysis, by key market participants
4.1.1 Ansoff Matrix
4.2 Major deals & strategic alliances analysis
4.2.1 Joint Ventures
4.2.2 Licensing and Partnerships
4.2.3 Technological Collaborations
4.3 Company/Competition Categorization
4.4 Vendor Landscape
4.4.1 List Of Key Distributors and Channel Partners
4.4.2 Key Customers
4.5 Public Companies
4.5.1 Company Market Position Analysis
4.6 Private Companies
4.6.1 List Of Key Emerging Companies
4.6.2 Regional Network Map
Chapter 5 NASH Biomarkers Market: Type Business Analysis
5.1 Definition and Scope
5.2 Type Market Share Analysis, 2021 & 2030
5.3 Global NASH Biomarkers Market, By Type, 2018 To 2030
5.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.4.1 Serum Biomarkers
5.4.1.1 Serum Biomarkers Market 2018 – 2030 (USD Million)
5.4.2 Hepatic Fibrosis Biomarkers
5.4.2.1 Hepatic Fibrosis Biomarkers Market, 2018 – 2030 (USD Million)
5.4.3 Apoptosis Biomarkers
5.4.3.1 Apoptosis Biomarkers Market, 2018 – 2030 (USD Million)
5.4.4 Oxidative Stress Biomarkers
5.4.4.1 Oxidative Stress Biomarkers Market, 2018 – 2030 (USD Million)
5.4.5 Others
5.4.5.1 Others Market, 2018 – 2030 (USD Million)
Chapter 6 NASH Biomarkers Market: End-Use Business Analysis
6.1 Definition and Scope
6.2 End-Use Market Share Analysis, 2021 & 2030
6.3 Global NASH Biomarkers Market, By End-Use, 2018 To 2030
6.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.4.1 Pharma & CRO Industry
6.4.1.1 Pharma & CRO Industry Market 2018 – 2030 (USD Million)
6.4.2 Hospitals
6.4.2.1 Hospitals Market, 2018 – 2030 (USD Million)
6.4.3 Diagnostic Labs
6.4.3.1 Diagnostic Labs Market, 2018 – 2030 (USD Million)
6.4.4 Academic Research Institutes
6.4.4.1 Academic Research Institutes Market, 2018 – 2030 (USD Million)
Chapter 7 NASH Biomarkers Market: Regional Business Analysis
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2021 & 2030
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 MEA
7.6 Market Size, & Forecasts, Trend Analysis, 2021 to 2030
7.7 North America
7.7.1 North America NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.7.2 U.S.
7.7.2.1 U.S. NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.7.3 Canada
7.7.3.1 Canada NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.8 Europe
7.8.1 Europe NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.8.2 U.K.
7.8.2.1 U.K. NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.8.3 Germany
7.8.3.1 Germany NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.8.4 France
7.8.4.1 France NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.8.5 Italy
7.8.5.1 Italy NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.8.6 Spain
7.8.6.1 Spain NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.9 Asia Pacific
7.9.1 Asia Pacific NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.9.2 Japan
7.9.2.1 Japan NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.9.3 China
7.9.3.1 China NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.9.4 India
7.9.4.1 India NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.9.5 Australia
7.9.5.1 Australia NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.9.6 South Korea
7.9.6.1 South Korea NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.10 Latin America
7.10.1 Latin America NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.10.2 Brazil
7.10.2.1 Brazil NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.10.3 Mexico
7.10.3.1 Mexico NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.10.4 Argentina
7.10.4.1 Argentina NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.11 MEA
7.11.1 MEA NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.11.2 South Africa
7.11.2.1 South Africa NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.11.3 Saudi Arabia
7.11.3.1 Saudi Arabia NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.11.4 UAE
7.11.4.1 UAE NASH Biomarkers Market, 2018 – 2030 (USD Million)
Chapter 8 NASH Biomarkers Market: Company Profiling
8.1 Company Profiles
8.1.1. GENFIT
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2. Prometheus Laboratories
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3. AstraZeneca
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4. Siemens Medical Solutions USA, Inc.
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5. Bristol-Myers Squibb Company
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic initiatives
8.1.6. BioPredictive
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Product benchmarking
8.1.6.4 Strategic initiatives
8.1.7. Quest Diagnostics
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic initiatives
8.1.8 Exalenz Bioscience Ltd
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic initiatives
8.1.9 Pfizer, Inc.
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic initiatives
8.1.10 Laboratory Corporation of America Holdings
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic initiatives